New UK Government Promises Reform Of NICE - And Value-Added Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE reforms are included in the legislative timetable of the new UK coalition government as the institute continues its work, recommending AstraZeneca's Iressa for lung cancer and rejecting Bayer's Nexavar for liver cancer.